确定影响癌症相关疲劳的相关因素,在化学疗法期间扩散大B细胞淋巴瘤患者
Xiu-Qiao Hao1, Xiang-Dan Yang1, Yue Qi2
1Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
World journal of psychiatry
|July 25, 2024
概括
在接受化疗的扩散性大B细胞淋巴瘤 (DLBCL) 患者中,与癌症相关的疲劳 (CRF) 受几个因素的影响. 瘤阶段,化疗周期,自我效能,焦虑和抑郁症显著影响CRF水平.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 精神瘤学 精神瘤学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种普遍存在的恶性瘤,需要化疗.
- 化疗虽然有效,但往往会导致严重的副作用,如疲劳.
- 了解癌症相关疲劳 (CRF) 对于改善患者在治疗期间的生活质量至关重要.
研究的目的:
- 在接受化疗的DLBCL患者中调查与CRF相关的因素.
- 评估CRF,焦虑,抑郁和正念之间的关系.
主要方法:
- 对62名DLBCL患者的电子病历进行了回顾性分析.
- 使用了Piper疲劳量表,匹兹堡睡眠质量指数,五方面正念问卷,自我评价焦虑量表和自我评价抑郁量表.
- 采用单变量和多变量回归分析来确定CRF预测因子.
主要成果:
- 平均CRF得分为5.74±2.51. 平均CRF得分是5.74±2.51. 平均CRF得分是5.74±2.51. 平均CRF得分是5.74±2.51.
- 疲劳的严重程度在各个维度上有所不同:认知 (轻度),行为 (中度) 和情绪 (严重).
- CRF与癌症经验正相关,与治疗疗效负相关;瘤阶段,化疗周期,自我疗效,焦虑和抑郁是重要因素.
结论:
- CRF受到瘤分期,化疗周期,自我效能和心理状态 (焦虑,抑郁) 的显著影响.
- 感知控制水平与CRF有显著的相关性.
- 这些发现强调了DLBCL患者CRF的多因素性质.
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
01:21Cancer Survival Analysis
336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
157
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
157